Skip to main content

Table 1 Patient characteristics and demographics

From: Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis

 

All patients (n = 98)

Remissiona (n = 76)

Active diseasea (n = 22)

Age, years, median (range)

53 (19–85)

68 (24–84)

63 (19–85)

Disease duration, years, median (range)

6 (0–50)

7 (0–50)

0.5 (0–25)

GPA, %, (n)

76 (74)

74 (56)

82 (18)

MPA, %, (n)

24 (24)

26 (20)

18 (4)

PR3-ANCA, %, (n)

63 (62)

61 (46)

73 (16)

MPO-ANCA, %, (n)

30 (30)

32 (24)

27 (6)

ANCA negativeb

5 (5)

5 (4)

0 (0)

BVAS3, median (range)

0 (0–16)

0 (0–0)

5 (1–16)

Leukocytes, 109/L, median (range)c

6.4 (3–13.7)

6.2 (3.2–13.7)

7.9 (3–12)

p-creatinine, μmol/L, median (range)

103 (54–805)

98 (61–635)

154 (54–805)

p-CRP, mg/L, median (range)

2.9 (< 0.6–92)

2.6 (< 0.6–27)

5.7 (< 0.6–92)

Treatment

 Prednisone, %, median dose of treated

59 (6.25 mg/d)

53 (5 mg/d)

82 (17.5 mg/d)

 Azathioprine, % (n)

28 (27)

32 (24)

14 (3)

 Mycophenolate, % (n)

8 (8)

11 (8)

0 (0)

 Rituximab, % (n)

20 (20)

21 (16)

18 (4)

 Methotrexate, % (n)

14 (14)

13 (10)

18 (4)

 Cyklophosphamide, % (n)

13 (13)

7 (5)

36 (8)

 No current treatment, % (n)

12 (12)

14 (11)

9 (3)

  1. BVAS3 Birmingham Vasculitis Activity Score version 3, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibodies, PR3 proteinase 3, CRP C-reactive protein
  2. aPatients in remission have BVAS3 = 0 and patients with active disease BVAS3 ≥ 1
  3. bANCA data is missing on one patient and one was double positive
  4. cReference range 3.5–8.8 109/L. Treatment at the time of sampling except for Rituximab that is reported as given at any time during the disease